FDA.reportPublic FDA data

NATALIZUMAB Pharmacologic Class Indexing

Class set ID
bd5f1d25-69f2-4da3-9855-a10ead41845f
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use TYRUKO ® safely and effectively. See full prescribing information for TYRUKO . TYRUKO (natalizumab-sztn) injection, for intravenous use Initial U.S. Approval: 2023 TYRUKO (natalizumab-sztn) is biosimilar* to TYSABRI ® (natalizumab).Sandoz Inc2025103113
These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI. TYSABRI (natalizumab) injection, for intravenous use Initial U.S. Approval: 2004Biogen Inc.2025032147